Study suggests genetics as a cause, not just a risk, for some Alzheimer's
The new designation could broaden the scope of efforts to develop treatments, including gene therapy, and affect the design of clinical trials.
Source: bostonglobe.com
Michael Greicius News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Michael Greicius. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Michael Greicius Today - Breaking & Trending Today
Research May Result in Big Spike of Alzheimer's Diagnoses
A new study has the potential to lead to a dramatic spike in the number of diagnosed Alzheimer's cases in the US—as in, hundreds of thousands of people who aren't...
Source: newser.com
Therapeutic nihilism? Alzheimer's drug adoption in US slowed by scepticism
Food and Drug Administration approved Leqembi last year
Source: dunyanews.tv
Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why - Biogen (NASDAQ:BIIB)
Discover the challenges facing Leqembi, the first Alzheimer's drug shown to slow progression. Skepticism among doctors and concerns about efficacy and costs hinder widespread adoption despite FDA approval.
Source: benzinga.com
Alzheimer's drug adoption in US slowed by doctors' skepticism | WSAU News/Talk 550 AM · 99.9 FM
(Repeats to additional subscribers with no changes to text ) By Julie Steenhuysen CHICAGO (Reuters) -Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer's, Eisai and Biogen's Leqembi is facing an unexpected hurdle...
Source: wsau.com